Opus Genetics Details 2025 Progress and 2026 Milestones

Opus Genetics ( (IRD) ) has provided an announcement.

On January 8, 2026, Opus Genetics highlighted its 2025 operational progress and outlined key milestones expected in 2026, underscoring the maturation of its multi-asset ophthalmic pipeline and strengthening financial position. In 2025, the company advanced two lead gene therapies—OPGx-BEST1 for BEST1-related inherited retinal disease, which began dosing patients in a Phase 1/2 trial, and OPGx-LCA5 for Leber congenital amaurosis, which produced positive Phase 1/2 safety and efficacy data in adults and pediatric patients and is being advanced into an adaptive pivotal Phase 3 study. The pipeline benefited from multiple regulatory designations for OPGx-LCA5, including Rare Pediatric Disease, Orphan Drug and RMAT status, while OPGx-BEST1 is being positioned for similar regulatory pathways, and preclinical IRD programs targeting RHO, CNGB1, MERTK, RDH12-LCA and NMNAT1 moved toward first-in-human studies with support from patient advocacy partnerships and non-dilutive funding. Opus also submitted a supplemental new drug application for Phentolamine Ophthalmic Solution 0.75% for presbyopia and continued a pivotal Phase 3 trial (LYNX-3) in keratorefractive patients experiencing low-light visual disturbances. Financially, as of September 30, 2025, Opus held $30.8 million in cash and equivalents and subsequently raised about $23 million in a registered direct equity offering, bringing its cash balance to more than $50 million and extending its operational runway into the second half of 2027, a position that supports the planned clinical readouts and regulatory milestones that could influence its future revenue potential and competitive standing in retinal gene therapy.

The most recent analyst rating on (IRD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.

Spark’s Take on IRD Stock

According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.

The score is held back primarily by weak financial performance—large losses and sustained cash burn—despite low leverage. Technicals are mixed with slightly negative momentum, while corporate events provide a meaningful offset via positive clinical/regulatory progress. Valuation remains constrained by loss-making results and no dividend support.

To see Spark’s full report on IRD stock, click here.

More about Opus Genetics

Opus Genetics, Inc., based in Research Triangle Park, N.C., is a clinical-stage biopharmaceutical company focused on developing AAV-based gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases. Its pipeline includes seven gene therapy programs led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, alongside additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule ophthalmic therapy, into additional indications including presbyopia and low-light visual disturbances following keratorefractive surgery.

Average Trading Volume: 511,895

Technical Sentiment Signal: Hold

Current Market Cap: $143.4M

For detailed information about IRD stock, go to TipRanks’ Stock Analysis page.